Cynata Therapeutics Share Price and Company Fundamentals
Last traded: Today at 5:47 AM
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company has a partnership with Monash University, University of Sydney, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, Critical Care Research Group, Massachusetts General Hospital, and the Royal College of Surgeons in Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia.
|Primary activities||Clinical stage biotechnology company specialising in cell therapeutics|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||100 Cubitt Street Level 3 Cremorne VIC 3121 Australia|
|Phone / Fax||613 9114 2220 /|
|Share registry||AUTOMIC REGISTRY SERVICES|
Cynata Therapeutics does not pay dividends.
As of Jul 2021, following are the company executives and directors listed on Cynata Therapeutics.
|Dr. Ross Alexander MacDonald Ph.D.||MD, CEO & Exec. Director||62||454.17k|
|Dr. Kilian Kelly||Chief Operating Officer||367.19k|
|Mr. Peter Gordon Webse M.A.I.C.D., B.Bus, FGIA, FCIS, FCPA, MAICD||Company Sec.||57||140k|
|Dr. Suzanne Lipe||VP of Alliance Management||70||217.69k|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Cynata Therapeutics is 67.34M and its enterprise value is 45.75M. The enterprise value to revenue ratio of CYP is 17.67.
The CYP's stocks Beta value is 0.43 making it 57% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Cynata Therapeutics (CYP)
Cynata Therapeutics (ASX:CYP) Frequently Asked Questions
1. What is Cynata Therapeutics's Stock Symbol?
Cynata Therapeutics trades on ASX under the ticker symbol "CYP".
2. What is Cynata Therapeutics's stock price today?
One share of CYP stock can currently be purchased for approximately $0.47.
3. How can I contact Cynata Therapeutics?
Cynata Therapeutics's mailing address is 100 Cubitt Street Level 3 Cremorne VIC 3121 Australia. The company can be reached via phone at 613 9114 2220.
4. What is Cynata Therapeutics's official website?
The official website of Cynata Therapeutics is http://www.cynata.com.
5. Which share registry manages Cynata Therapeutics's stock?
Cynata Therapeutics's stock is managed by AUTOMIC REGISTRY SERVICES.